No OS Benefit from Continuous as Compared with Fixed-Duration Maintenance Therapy with Lenalidomide in Patients with Newly Diagnosed Multiple Myeloma By Ogkologos - August 13, 2026 49 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ENDURANCE study Source RELATED ARTICLESMORE FROM AUTHOR Perioperative Pembrolizumab Plus Neoadjuvant Chemotherapy Continues to Prolong EFS and OS in Patients with Stage II, IIIA, or IIIB (N2) NSCLC Patient Guide in Soft Tissue Sarcoma Now Available Also in Ukrainian Adjuvant Pembrolizumab Continues to Demonstrate Benefit in DFS and OS Among Patients with ccRCC MOST POPULAR FDA Grants Regular Approval to Rucaparib for Metastatic Castration-Resistant Prostate Cancer January 29, 2026 Triple Blockade Demonstrates High Response Rates in Metastatic Melanoma October 14, 2020 On legacy giving: “It allows me to give something more meaningful... October 13, 2021 Pregnancy is Safe After Early Breast Cancer in Young Women with... July 17, 2020 Load more HOT NEWS Activity and Manageable Toxicity of Pembrolizumab in Some Rare and Ultrarare... Let’s get to the bottom of it – 7 common cancer... Finding Purpose in Sharing Your Story: A Q&A With Esophageal Cancer... ASCO 2023 roundup: Blood tests, drugs and exercise
